Abstract
The role of sibutramine as an effective adjunct to diet and exercise in weight management programmes has been proven in clinical trials. Although the reality of managing obesity in clinical practice is very different from that of a controlled clinical trial, there is good evidence that sibutramine is an easy-to-use and highly effective additional therapy when used in everyday practice to manage obesity and its complications. It is possible to predict which patients will respond well to sibutramine treatment, and to modify programmes and support to ensure the best outcome for patients, whatever their clinical circumstances.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Finer, N. Sibutramine in clinical practice. Int J Obes 25 (Suppl 4), S12–S15 (2001). https://doi.org/10.1038/sj.ijo.0801932
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0801932
Keywords
This article is cited by
-
Sibutramine and the sympathetic nervous system in obese humans
Clinical Autonomic Research (2005)